The Biotechnology sector roared to life in 2017, posting a record 209 transactions. That’s 20% higher than the 174 deals announced in 2016. The previous record for the sector was set in 2009, with 193 transactions announced in the space. Spending for those 209 deals in 2017 didn’t set new records, but did post an […]
Early in July, Sanofi (NYSE: SNY) announced an acquisition and a divestment, both affecting its vaccine business. In a recent annual filing, Sanofi labelled its vaccine unit as an area of priority to sustain its leadership role. To that end, the company has expanded its influenza vaccine portfolio and shed its small pox vaccine business, including […]
Drug companies and managed care organizations are working to keep prices from rising precipitously. Then there’s Pfizer.
There’s been a sharp drop in Pharmaceutical deals in the first quarter of 2017, compared with a year ago. What’s up with that?
Johnson & Johnson swallowed hard and upped its bid for Swiss biotech Actelion, winning the deal with a $30.2 billion bid.
The pharmaceutical industry has been the behemoth of healthcare M&A, usually accounting for the largest dollar amounts spent in any given year and often one of the most active in terms of number of transactions.
Deal volume in the Biotechnology sector is poised to surpass last year’s record-setting 160 transactions. With two weeks left in 2016, deal volume has reached 159 transactions. The activity in this sector shows no signs of abating, and will probably carry through the first half of 2017, at least.
The pharmaceutical industry has largely given up on in-house research and development, saying that the R&D timeline is too costly, long and uncertain to fund with shareholders’ money. The industry has gone from bolt-on acquisitions of smaller companies with marketed products to battling it out for clinical-stage drug candidates. What’s surprised some industry observers is […]
Forget those early- to mid-stage clinical candidates. Pfizer Inc. (NYSE: PFE) jumped the line with its $13.5 billion deal for oncology drug maker Medivation Inc. (NASDAQ: MDVN). The target’s primary product is XTANDI® (enzalutamide), an androgen receptor inhibitor, the leading novel hormone therapy for the treatment of prostate cancer. Pfizer will pay $81.50 per share in […]
The days of mega-mergers in the pharmaceutical sector aren’t necessarily over, but those deals will be fewer and farther between, going forward. Nearly 60 deals have been announced in 2016 through the middle of May, and just 17 have an entire company as the target. The largest, so far, is Shire‘s (NASDAQ: SHPG) $32 billion […]